Krystal Biotech logo
Krystal Biotech
KRYS | NASDAQ
Chart Builder DCF Calculator
$297.90
-$7.33 (-2.40%)
At close: Nov 16, 2026, 4:00 PM ET
$297.90
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Krystal Biotech Company Profile

Company profile explained

Company Profile

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Key Executives

Name Position
Krish S. Krishnan Founder, Chairman, President & Chief Executive Officer
Christine Wilson Senior VP & Head of US Commercial
David Chien Senior Vice President of Clinical Development
John Karakkal Vice President of North American Sales & Marketing
John Thomas EVP, General Counsel & Corporate Secretary
Josh Suskin Senior Director & Head of US Human Resources
Kathryn A. Romano Executive Vice President & Chief Accounting Officer
Laurent Goux Executive VP & Head of International
Stephane Paquette Senior Vice President of Corporate Development
Suma Krishnan Founder, President of R&D and Director

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 15, 2026 8-K Current Report
Sep 16, 2026 4 Filing
Sep 16, 2026 4 Filing
Sep 16, 2026 4 Filing
Sep 16, 2026 4 Filing
Sep 16, 2026 4 Filing
Sep 16, 2026 4 Filing
Sep 04, 2026 4 Filing
View All SEC Filings ➞
Krystal Biotech
Krystal Biotech logo
Country United States
IPO Date Sep 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 295
CEO Krish S. Krishnan

Contact Details

2100 Wharton Street Pittsburgh, Pennsylvania 15203 United States

Stock Details

Ticker Symbol KRYS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001711279
CUSIP Number 501147102
ISIN Number US5011471027
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.